消化系統疾病治療市場－2026-2032年全球市場預測

預計到 2032 年，胃腸道疾病治療市場將成長至 577.1 億美元，複合年成長率為 4.11%。

主要市場統計數據
基準年 2025	435.2億美元
預計年份：2026年	453億美元
預測年份：2032年	577.1億美元
複合年成長率 (%)	4.11%

胃腸道疾病治療執行摘要

從臨床、監管和商業角度來看，胃腸道疾病的治療已成為高度關注的重點，因為包括發炎性疾病、功能性疾病、酸相關疾病、動力障礙性疾病、肝臟疾病、胰臟疾病、感染疾病和微生物群相關疾病在內的多種胃腸道疾病持續影響大量患者。治療方法涵蓋生物製藥、小分子藥物、抗生素、抑酸劑、止吐藥、止瀉藥、瀉藥、酵素替代療法、膽汁酸調節劑、免疫調節劑、益生菌、新興生物製藥和細胞標靶治療。推動市場需求的因素包括發炎性腸道疾病、大腸激躁症躁症、胃食道逆流、消化性潰瘍、乳糜瀉、便秘、腹瀉相關疾病以及與消化器官系統疾病、癌症治療、老齡化和抗生素抗藥性相關的胃腸道併發症等日益嚴重的臨床負擔。

胃腸道疾病治療領域的變革性變化

胃腸道疾病的治療方法正從廣泛的症狀管理轉向標靶治療。在發炎性腸道疾病中，治療策略正從傳統的皮質類固醇和免疫抑制劑轉向生技藥品和針對腸道發炎相關免疫通道的口服小分子藥物。在酸相關疾病中，臨床醫生正在權衡質子幫浦抑制劑和組織胺H2受體拮抗劑的廣泛應用與對新型抑酸機制和長期安全性管理日益成長的興趣。隨著神經調控、腸-腦軸科學、飲食療法和微生物組相關干預措施的臨床意義日益凸顯，功能性胃腸疾病的治療也不斷發展。

人工智慧對胃腸道疾病治療的累積影響

人工智慧（AI）正整體成為胃腸道疾病治療領域，特別是藥物研發、臨床實驗室設計、生物標記識別、疾病監測和個人化治療等方面的強大驅動力。人工智慧平台能夠分析多組體學資料集、內視鏡影像、電子健康記錄、病理報告、微生物組譜以及患者自述結局，從而識別疾病亞型並預測治療反應。在發炎性腸道疾病領域，人工智慧在輔助內視鏡評估、檢測黏膜發炎和規範影像解讀方面展現出巨大潛力，有望提高臨床檢測和臨床決策的一致性。

全球胃腸道疾病治療市場的關鍵區域洞察

由於亞太地區患者群體龐大、多個經濟區人口老化、都市區發炎性腸道疾病診斷率上升、部分地區胃腸道感染疾病高發生率以及專科醫療服務覆蓋範圍不斷擴大，該地區在胃腸道疾病治療領域的重要性日益凸顯。儘管中國、印度、日本、韓國和澳洲等國正在加強其臨床研究體系，但區域醫療體系仍在努力應對感染性和慢性胃腸道疾病的雙重負擔。內視鏡檢查的普及、部分市場醫保覆蓋範圍的擴大以及醫生對生技藥品、生物類似藥和高潛力小分子藥物的認知不斷加深，都促進了治療的推廣。

小組對胃腸道疾病治療的關鍵見解

在東協，都市化、飲食結構改變、醫療保健投入增加以及診斷手段的普及，提高了人們對酸相關疾病、發炎性腸道疾病、肝臟相關消化系統疾病和感染性胃腸道疾病的認知，從而推動了胃腸道健康領域的穩步發展。儘管區域間在報銷制度、專科醫生資源和公共衛生基礎設施方面的差異會影響先進療法的推廣速度，但基本藥物、疫苗接種（如適用）以及合理使用抗生素仍然是重中之重。

各國在胃腸道疾病治療的主要見解

美國在引進先進的胃腸道疾病治療方法方面處於主導，這得益於其廣泛的專家網路、完善的臨床實驗室基礎設施、積極應用生技藥品和口服標靶治療，以及成熟的醫保支付管理。加拿大則強調實證報銷、專家主導的發炎性腸道疾病診療以及公私合營的醫療服務管道。在墨西哥，胃腸道疾病的診斷和治療服務正在不斷擴展，但公立和都市區都市區環境之間的服務可及性存在差異。

胃腸道疾病治療領域領導者使用的實用建議。

產業領導者應優先開發差異化療法，以滿足發炎性腸道疾病、功能性胃腸疾病、復發性性行為感染、酸相關疾病、動力障礙以及微生物組介導疾病等領域尚未滿足的明確需求。臨床計畫的設計應圍繞有意義的終點指標展開，例如持續緩解、黏膜治療、症狀緩解、減少類固醇用量、避免住院、減少感染疾病復發以及改善患者自述的生活品質。早期應用生物標記策略有助於患者分層，提高臨床試驗效率，並為保險公司提供更有力的證據。

胃腸道疾病治療的情報調查方法

本執行摘要採用系統的二手資料研究方法編寫，使用了經核實的公共領域和行業相關資訊來源，包括監管指南、臨床實踐指南、同行檢驗的醫學文獻、公共衛生出版物、藥物警戒資源、衛生技術評估（HTA）框架以及疾病特異性臨床證據。該研究途徑調查方法強調從臨床、監管、流行病學和醫療服務觀點進行三角檢驗，以確保對胃腸道疾病治療的解讀具有平衡性。

結論：胃腸道疾病治療的策略性展望

胃腸道疾病的治療正經歷科學多元化、臨床改進和對實際價值日益課責的時期。這一領域正從傳統的症狀管理擴展到標靶免疫學、微生物組學、基於生物標記的治療、先進的抑酸治療、數位化監測和人工智慧驅動的檢查。無論在何處，其應用都受到疾病負擔、診斷基礎設施、報銷政策、專家資源、經濟負擔以及對長期安全性的預期等因素的影響。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 新的商機
• 下一代經營模式
• 工業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 市場動態
• 波特五力分析
• PESTLE分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：胃腸道疾病治療市場：依適應症分類

• 與酸相關的疾病
  • 消化不良
  • 胃食道逆流症
  • 消化性潰瘍
• 傳染性腸胃炎
  • 細菌性腸胃炎
  • 寄生蟲感染疾病
  • 病毒性腸胃炎
• 發炎性腸道疾病
  • 克隆氏症
  • 潰瘍性大腸炎
• 大腸激躁症
  • 便秘型
  • 腹瀉型
  • 混合型

第8章：胃腸道疾病治療市場：依藥物類別分類

• 氨基水楊酸類藥物
• 抗生素
  • Ciprofloxacin
  • 甲硝唑
  • Rifaximin
• 止瀉
• 解痙藥
• 生物製劑
  • 抗整合素藥物
  • 抗腫瘤壞死因子製劑
  • 白細胞介素抑制劑
• H2受體拮抗劑
• 瀉藥
• 質子幫浦抑制劑

第9章：胃腸道疾病治療市場：依給藥途徑分類

• 口服
• 腸外
• 外用

第10章 胃腸道疾病治療市場：以劑型分類

• 粉末
• 懸浮液
• 片劑和膠囊

第11章：胃腸道疾病治療市場：依最終使用者分類

• 診所
• 家庭醫療保健
• 醫院

第12章：胃腸道疾病治療市場：依通路分類

• 離線
• 線上

第13章 消化系統疾病治療市場：依地區分類

• 亞太地區
• 北美洲
• 拉丁美洲
• 歐洲
• 中東
• 非洲

第14章：胃腸道疾病治療市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章：胃腸道疾病治療市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章 競爭格局

• 2025年市佔率分析
• FPNV定位矩陣，2025
• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年

第17章：公司簡介

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Ferring BV
• Gilead Sciences, Inc.
• GSK plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Organon & Co.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• UCB SA
• Viatris Inc.

The Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 57.71 billion at a CAGR of 4.11% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 43.52 billion
Estimated Year [2026]	USD 45.30 billion
Forecast Year [2032]	USD 57.71 billion
CAGR (%)	4.11%

Gastrointestinal Diseases Therapeutics Executive Summary

Gastrointestinal diseases therapeutics are entering a high-priority phase of clinical, regulatory, and commercial attention as digestive disorders continue to affect large patient populations across inflammatory, functional, acid-related, motility, hepatic, pancreatic, infectious, and microbiome-associated conditions. The therapeutic landscape spans biologics, small molecules, antibiotics, acid suppressants, antiemetics, antidiarrheals, laxatives, enzyme replacement therapies, bile acid modulators, immunomodulators, probiotics, and emerging live biotherapeutic and cell-targeted approaches. Demand is being shaped by the rising clinical burden of inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux disease, peptic ulcer disease, celiac disease, constipation, diarrhea-associated disorders, and gastrointestinal complications linked to metabolic disease, oncology treatment, aging, and antimicrobial resistance.

The sector is increasingly defined by precision gastroenterology, earlier diagnosis, biomarker-guided treatment selection, patient-reported outcome integration, and a shift from symptom control toward mucosal healing, sustained remission, infection prevention, and quality-of-life improvement. Regulatory agencies continue to emphasize robust clinical endpoints, long-term safety monitoring, pharmacovigilance, and real-world evidence for chronic gastrointestinal therapies. At the same time, healthcare systems are placing greater attention on treatment adherence, affordability, specialty drug access, and reducing hospitalization linked to severe gastrointestinal flare-ups or complications. For industry stakeholders, the strategic opportunity lies in developing differentiated therapies that address unmet needs while aligning with payer expectations, clinical guidelines, antimicrobial stewardship, and digitally enabled care pathways.

Transformative Shifts in the Gastrointestinal Therapeutics Landscape

The gastrointestinal diseases therapeutics landscape is shifting from broad symptom management to targeted, mechanism-driven care. In inflammatory bowel disease, treatment strategies are moving beyond conventional corticosteroids and immunosuppressants toward biologics and oral small molecules that target immune pathways associated with intestinal inflammation. In acid-related disorders, clinicians are balancing the widespread use of proton pump inhibitors and histamine-2 receptor antagonists with growing interest in newer acid suppression mechanisms and improved long-term safety stewardship. Functional gastrointestinal disorders are also evolving as neuromodulation, gut-brain axis science, dietary management, and microbiome-related interventions gain clinical relevance.

A major transformation is the growing role of the gut microbiome as both a therapeutic target and a diagnostic signal. Evidence linking microbial composition to recurrent infection, inflammatory activity, metabolic dysfunction, and treatment response has accelerated research into live biotherapeutics, microbiota restoration, bacteriophage approaches, and microbiome-informed companion diagnostics. Another shift involves the expansion of home-based and decentralized care, including self-administered therapies, remote symptom tracking, virtual gastroenterology consultations, and digital adherence support for chronic conditions such as inflammatory bowel disease and irritable bowel syndrome.

Regulatory expectations are also changing. Authorities increasingly require stronger evidence on sustained response, steroid-free remission, mucosal healing, infection risk, malignancy risk, and post-authorization safety. Payers and health technology assessment bodies are scrutinizing comparative effectiveness, treatment sequencing, and total cost of care, particularly for specialty therapeutics. These changes are encouraging developers to design patient-centric trials, incorporate real-world data, and demonstrate measurable benefits beyond conventional clinical response.

Cumulative Impact of Artificial Intelligence on Gastrointestinal Therapeutics

Artificial intelligence is becoming a practical accelerator across gastrointestinal diseases therapeutics, particularly in drug discovery, clinical trial design, biomarker identification, disease monitoring, and treatment personalization. AI-enabled platforms can analyze multi-omics datasets, endoscopy images, electronic health records, pathology reports, microbiome profiles, and patient-reported outcomes to identify disease subtypes and predict therapeutic response. In inflammatory bowel disease, AI has shown strong potential in supporting endoscopic assessment, detecting mucosal inflammation, and standardizing image interpretation, which may improve trial consistency and clinical decision-making.

AI is also improving research efficiency by identifying eligible trial participants, predicting dropout risk, optimizing site selection, and detecting safety signals from real-world datasets. Natural language processing can extract relevant gastrointestinal symptoms, medication histories, and comorbidities from unstructured clinical notes, helping researchers and clinicians better understand disease trajectories. In pharmacovigilance, AI-based signal detection can support earlier identification of adverse events associated with immunosuppressive agents, biologics, antibiotics, and chronic acid suppression therapies.

The cumulative impact of AI is strongest when integrated with clinical validation, transparent governance, and data privacy safeguards. Gastrointestinal disease datasets are often fragmented across endoscopy centers, pathology laboratories, hospitals, pharmacies, and patient apps, making interoperability and data quality essential. Industry leaders that deploy AI responsibly can improve target discovery, accelerate evidence generation, refine patient stratification, and support value-based care without replacing clinician judgment. The next competitive edge will come from combining AI with biomarker science, real-world evidence, and patient-centered digital health infrastructure.

Key Regional Insights Across Global Gastrointestinal Therapeutics

Asia-Pacific is becoming increasingly important in gastrointestinal diseases therapeutics due to its large patient base, aging demographics in several economies, rising diagnosis of inflammatory bowel disease in urban populations, high prevalence of gastrointestinal infections in parts of the region, and expanding access to specialty care. Countries such as China, India, Japan, South Korea, and Australia are strengthening clinical research capacity, while regional healthcare systems continue to manage the dual burden of infectious gastrointestinal disease and chronic digestive disorders. Improved endoscopy availability, broader insurance coverage in select markets, and growing physician familiarity with biologics, biosimilars, and advanced small molecules are shaping treatment adoption.

North America remains one of the most advanced regions for gastrointestinal therapeutics, supported by established specialty care networks, high diagnostic penetration, broad access to endoscopy, strong use of biologics for inflammatory bowel disease, and extensive real-world evidence generation. The region also demonstrates high awareness of acid-related disorders, irritable bowel syndrome, colorectal screening pathways, and chronic gastrointestinal disease management. Regulatory rigor, payer utilization controls, antimicrobial stewardship, and demand for comparative effectiveness evidence continue to shape therapy access and treatment sequencing.

Latin America presents a heterogeneous but increasingly active environment for gastrointestinal therapeutics. Brazil and Mexico are key centers for diagnosis, clinical practice development, and specialty treatment adoption, while disparities in public and private healthcare access influence treatment continuity. The region continues to manage infectious gastrointestinal conditions, Helicobacter pylori-related disease, inflammatory bowel disease, functional bowel disorders, and liver-associated digestive disorders, creating demand for both affordable essential medicines and advanced therapies.

Europe is characterized by strong clinical guideline adoption, mature gastroenterology networks, advanced inflammatory bowel disease management, and centralized health technology assessment processes. The region places high emphasis on evidence-based prescribing, biosimilar integration, cost-effectiveness, antimicrobial stewardship, and post-marketing safety. Western European countries generally have broader access to advanced therapies, while Central and Eastern European markets continue to expand specialty care infrastructure and reimbursement pathways.

The Middle East is experiencing rising demand for gastrointestinal therapeutics as lifestyle-related disorders, obesity, diabetes, inflammatory bowel disease, and acid-related conditions become more visible in clinical practice. Gulf healthcare systems are investing in tertiary hospitals, specialist training, diagnostic capacity, and access to innovative medicines, while other parts of the region face access variability. Africa faces a complex gastrointestinal disease burden that includes infectious diarrhea, parasitic disease, Helicobacter pylori infection, malnutrition-associated gastrointestinal complications, and an emerging recognition of chronic inflammatory and functional disorders. Access to diagnostics, medicine availability, cold-chain reliability, and healthcare infrastructure remain central determinants of therapeutic outcomes across the continent.

Key Group Insights for Gastrointestinal Diseases Therapeutics

ASEAN countries are witnessing steady advancement in gastrointestinal care as urbanization, dietary shifts, healthcare investment, and better diagnostic access increase recognition of acid-related disorders, inflammatory bowel disease, liver-linked digestive disease, and infectious gastrointestinal conditions. Regional differences in reimbursement, specialist availability, and public health infrastructure influence the pace of advanced therapy adoption, while essential medicines, vaccination where applicable, and antimicrobial stewardship remain core priorities.

The GCC is strengthening its position in digestive disease management through investment in specialist hospitals, digital health, advanced diagnostics, and access to innovative therapies. Rising rates of obesity, diabetes, reflux disease, fatty liver-associated gastrointestinal complications, and immune-mediated disorders are shaping clinical demand. Centralized procurement and national health transformation programs are also influencing formulary decisions, referral pathways, and care standardization.

The European Union represents a highly regulated and evidence-driven environment where gastrointestinal therapeutics are shaped by harmonized medicine authorization, country-level reimbursement assessments, clinical guideline adherence, biosimilar utilization, and pharmacovigilance. The EU's emphasis on real-world evidence, antimicrobial resistance control, cross-border clinical research, and equitable access supports structured adoption of both established and advanced therapies.

BRICS countries combine large patient populations with diverse healthcare systems, making them strategically important for gastrointestinal disease therapeutics. Brazil, Russia, India, China, and South Africa face varying burdens of infectious disease, inflammatory bowel disease, reflux disease, Helicobacter pylori infection, and functional gastrointestinal disorders. Expanding domestic manufacturing, clinical trial participation, public coverage initiatives, and regulatory modernization are influencing access, while affordability remains a defining factor.

G7 countries are among the most mature environments for advanced gastrointestinal therapeutics, with established regulatory systems, high clinical research activity, strong specialist networks, and broad availability of innovative medicines. However, cost containment, evidence thresholds, biosimilar competition, and patient access controls remain prominent. NATO member countries overlap significantly with high-income healthcare systems in North America and Europe, but access patterns vary by national reimbursement policy, defense-related health systems, and public sector procurement practices. Across these groups, the common strategic theme is the need to align innovation with clinical value, affordability, supply resilience, and long-term safety evidence.

Key Country Insights in Gastrointestinal Diseases Therapeutics

The United States leads in advanced gastrointestinal therapeutics adoption, supported by extensive specialist networks, clinical trial infrastructure, strong use of biologics and oral targeted therapies, and sophisticated payer management. Canada emphasizes evidence-based reimbursement, specialist-led inflammatory bowel disease care, and public-private access pathways. Mexico is expanding gastrointestinal diagnosis and treatment availability, though access varies between public and private systems and between urban and non-urban care settings.

Brazil is a major Latin American center for digestive disease care, with growing attention to inflammatory bowel disease, Helicobacter pylori management, reflux disease, infectious gastrointestinal disorders, and advanced therapies in specialized settings. The United Kingdom maintains strong guideline-driven gastroenterology practice, centralized health technology assessment, and structured inflammatory bowel disease care pathways. Germany has a highly developed specialist care system with broad diagnostic access, strong clinical research activity, and established use of biologics and biosimilars. France combines mature reimbursement processes with robust hospital-based gastroenterology networks and emphasis on safety monitoring. Russia faces a broad digestive disease burden with access shaped by regional healthcare capacity, reimbursement policies, and domestic medicine supply considerations. Italy and Spain both have strong gastroenterology expertise, active inflammatory bowel disease care networks, and increasing attention to biosimilar adoption, antimicrobial stewardship, and cost-effective treatment sequencing.

China is rapidly expanding its gastrointestinal therapeutics capabilities through broader hospital infrastructure, increased diagnosis of inflammatory bowel disease, high attention to Helicobacter pylori infection, and growing participation in clinical research. India faces a dual burden of infectious gastrointestinal disease and increasing chronic digestive disorders, with access influenced by affordability, urban-rural disparities, and expanding private healthcare capacity. Japan has advanced diagnostic standards, strong endoscopy utilization, aging-related digestive disease needs, and established use of innovative therapies under strict regulatory and reimbursement controls. Australia supports high-quality gastroenterology care through specialist services, public reimbursement mechanisms, and active management of inflammatory bowel disease and functional gastrointestinal disorders. South Korea combines advanced hospital systems, high endoscopy use, growing specialty medicine adoption, and strong digital health capabilities, making it an important market for evidence-driven gastrointestinal therapeutics.

Actionable Recommendations for Gastrointestinal Therapeutics Leaders

Industry leaders should prioritize differentiated therapeutic development that addresses clear unmet needs in inflammatory bowel disease, functional gastrointestinal disorders, recurrent infection, acid-related disease, motility disorders, and microbiome-mediated conditions. Clinical programs should be designed around meaningful endpoints such as durable remission, mucosal healing, symptom relief, steroid reduction, hospitalization avoidance, infection recurrence reduction, and patient-reported quality-of-life improvement. Incorporating biomarker strategies early can support patient stratification, improve trial efficiency, and strengthen payer-facing evidence.

Organizations should expand real-world evidence capabilities to demonstrate comparative effectiveness, long-term safety, adherence patterns, and total care impact. This is particularly important for biologics, oral targeted agents, chronic acid suppression therapies, antimicrobial regimens, and microbiome-based interventions. Collaboration with gastroenterologists, primary care providers, payers, patient groups, and digital health stakeholders can improve treatment pathway alignment, support earlier diagnosis, and reduce avoidable disease escalation.

To improve global access, leaders should tailor commercialization strategies to regional reimbursement systems, diagnostic infrastructure, and affordability constraints. Biosimilar readiness, patient support programs, supply chain resilience, cold-chain planning, and local regulatory engagement are essential for sustainable access. AI and digital tools should be used to enhance, not replace, clinical decision-making by supporting trial recruitment, adherence monitoring, safety surveillance, and personalized care. Finally, industry stakeholders should invest in antimicrobial stewardship, transparent safety communication, and evidence-based education to build trust among clinicians, payers, and patients.

Research Methodology for Gastrointestinal Therapeutics Intelligence

This executive summary is developed through a structured secondary research approach using verified public-domain and industry-relevant sources, including regulatory guidance, clinical practice guidelines, peer-reviewed medical literature, public health publications, pharmacovigilance resources, health technology assessment frameworks, and disease-specific clinical evidence. The methodology emphasizes triangulation across clinical, regulatory, epidemiological, and healthcare delivery perspectives to ensure balanced interpretation of gastrointestinal diseases therapeutics.

The analysis reviews therapeutic classes, disease burden indicators, treatment pathway evolution, regional healthcare characteristics, reimbursement considerations, innovation trends, and technology-enabled care models. Particular attention is given to inflammatory bowel disease, gastroesophageal reflux disease, irritable bowel syndrome, peptic ulcer disease, infectious gastrointestinal disorders, microbiome-associated conditions, liver-linked digestive disorders, motility disorders, and chronic digestive disease management. Regional, group, and country insights are synthesized qualitatively to reflect differences in diagnostic access, clinical infrastructure, regulatory expectations, payer requirements, and therapy adoption patterns.

The research approach deliberately excludes market sizing, market share analysis, and forecasting. Instead, it focuses on evidence-backed strategic intelligence, clinical relevance, and operational implications for stakeholders involved in gastrointestinal therapeutics development, access, and delivery.

Conclusion: Strategic Outlook for Gastrointestinal Diseases Therapeutics

Gastrointestinal diseases therapeutics are advancing through a period of scientific diversification, clinical precision, and increasing accountability for real-world value. The field is expanding from conventional symptom management to targeted immunology, microbiome science, biomarker-guided care, advanced acid suppression, digital monitoring, and AI-enabled research. Across regions, adoption is shaped by disease burden, diagnostic infrastructure, reimbursement policy, specialist availability, affordability, and long-term safety expectations.

The most resilient strategies will be those that combine differentiated mechanisms of action with strong safety evidence, patient-centered outcomes, scalable access models, and measurable healthcare system value. As chronic digestive disorders and infectious gastrointestinal conditions continue to place pressure on healthcare systems, stakeholders that align innovation with clinical evidence, responsible AI use, antimicrobial stewardship, and equitable access will be best positioned to support improved outcomes in gastrointestinal diseases therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastrointestinal Diseases Therapeutics Market, by Indication

• 7.1. Introduction
• 7.2. Acid-Related Disorders
  • 7.2.1. Dyspepsia
  • 7.2.2. Gastroesophageal Reflux Disease
  • 7.2.3. Peptic Ulcer Disease
• 7.3. Infectious Gastroenteritis
  • 7.3.1. Bacterial Gastroenteritis
  • 7.3.2. Parasitic Infections
  • 7.3.3. Viral Gastroenteritis
• 7.4. Inflammatory Bowel Disease
  • 7.4.1. Crohn's Disease
  • 7.4.2. Ulcerative Colitis
• 7.5. Irritable Bowel Syndrome
  • 7.5.1. Constipation-Predominant
  • 7.5.2. Diarrhea-Predominant
  • 7.5.3. Mixed Type

8. Gastrointestinal Diseases Therapeutics Market, by Drug Class

• 8.1. Introduction
• 8.2. Aminosalicylates
• 8.3. Antibiotics
  • 8.3.1. Ciprofloxacin
  • 8.3.2. Metronidazole
  • 8.3.3. Rifaximin
• 8.4. Antidiarrheals
• 8.5. Antispasmodics
• 8.6. Biologics
  • 8.6.1. Anti Integrin Agents
  • 8.6.2. Anti Tumor Necrosis Factor Agents
  • 8.6.3. Interleukin Inhibitors
• 8.7. H2 Receptor Antagonists
• 8.8. Laxatives
• 8.9. Proton Pump Inhibitors

9. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Oral
• 9.3. Parenteral
• 9.4. Topical

10. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

• 10.1. Introduction
• 10.2. Powder
• 10.3. Suspension
• 10.4. Tablet/Capsule

11. Gastrointestinal Diseases Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Clinic
• 11.3. Home Healthcare
• 11.4. Hospital

12. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Gastrointestinal Diseases Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Gastrointestinal Diseases Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Gastrointestinal Diseases Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AbbVie Inc.
• 17.3. Amgen Inc.
• 17.4. AstraZeneca PLC
• 17.5. Bausch Health Companies Inc.
• 17.6. Bayer AG
• 17.7. Biogen Inc.
• 17.8. Boehringer Ingelheim International GmbH
• 17.9. Bristol-Myers Squibb Company
• 17.10. Cipla Limited
• 17.11. Dr. Reddy's Laboratories Ltd.
• 17.12. Eli Lilly and Company
• 17.13. F. Hoffmann-La Roche Ltd
• 17.14. Ferring B.V.
• 17.15. Gilead Sciences, Inc.
• 17.16. GSK plc
• 17.17. Johnson & Johnson Services Inc.
• 17.18. Merck & Co., Inc.
• 17.19. Novartis AG
• 17.20. Novo Nordisk A/S
• 17.21. Organon & Co.
• 17.22. Pfizer Inc.
• 17.23. Sanofi S.A.
• 17.24. Sun Pharmaceutical Industries Limited
• 17.25. Takeda Pharmaceutical Company Limited
• 17.26. Teva Pharmaceutical Industries Ltd.
• 17.27. UCB SA
• 17.28. Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
• FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, RESEARCH DESIGN
• FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, RESEARCH FRAMEWORK
• FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, DATA TRIANGULATION
• FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
• FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
• FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
• FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
• FIGURE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
• FIGURE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
• FIGURE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
• FIGURE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
• FIGURE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
• FIGURE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

• TABLE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ACID-RELATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL DYSPEPSIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL DYSPEPSIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL DYSPEPSIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL PEPTIC ULCER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS GASTROENTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS GASTROENTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS GASTROENTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BACTERIAL GASTROENTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BACTERIAL GASTROENTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BACTERIAL GASTROENTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL VIRAL GASTROENTERITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL VIRAL GASTROENTERITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL VIRAL GASTROENTERITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL IRRITABLE BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL CONSTIPATION-PREDOMINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL CONSTIPATION-PREDOMINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL CONSTIPATION-PREDOMINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL DIARRHEA-PREDOMINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL DIARRHEA-PREDOMINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL DIARRHEA-PREDOMINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL MIXED TYPE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL MIXED TYPE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL MIXED TYPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL AMINOSALICYLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL AMINOSALICYLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL AMINOSALICYLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL CIPROFLOXACIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL CIPROFLOXACIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL CIPROFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL METRONIDAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL METRONIDAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL METRONIDAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL RIFAXIMIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL RIFAXIMIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL RIFAXIMIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL ANTIDIARRHEALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL ANTISPASMODICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL ANTISPASMODICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL ANTISPASMODICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL ANTI INTEGRIN AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL ANTI INTEGRIN AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL ANTI INTEGRIN AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL ANTI TUMOR NECROSIS FACTOR AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL ANTI TUMOR NECROSIS FACTOR AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL ANTI TUMOR NECROSIS FACTOR AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL PROTON PUMP INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL TABLET/CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL TABLET/CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL TABLET/CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 130. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 131. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 132. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 133. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 134. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 135. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 136. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 137. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 138. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 139. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 140. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 141. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 142. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 143. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 144. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 146. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 148. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 149. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 150. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 151. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 152. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 153. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 154. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 156. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 158. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 160. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 161. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 162. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 163. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 164. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 165. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 166. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 167. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 168. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 169. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 170. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 171. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 172. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 173. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 174. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 175. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 176. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 177. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 178. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 179. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 180. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 181. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 182. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 183. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 184. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 186. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 188. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 190. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 192. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 194. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 195. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 196. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 197. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 198. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 199. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 200. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 201. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 202. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 203. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 204. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 205. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 206. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 207. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 208. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 209. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 210. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 211. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 212. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 213. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 214. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 215. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 216. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 217. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 218. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 219. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 220. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 221. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 222. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 223. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 224. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 225. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 226. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 227. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 228. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 229. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 230. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 231. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 232. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 233. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 234. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 235. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 236. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 237. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 238. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 239. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 240. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 241. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 242. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 243. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 244. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 245. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 246. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 247. EUROPEAN UNION GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 248. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 249. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 250. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 251. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 252. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 253. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 254. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 255. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 256. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 257. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 258. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 259. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 260. BRICS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 261. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 262. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 263. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 264. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 265. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 266. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 267. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 268. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 269. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 270. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 271. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 272. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 273. G7 GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 274. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 275. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 276. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 277. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 278. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 279. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 280. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 281. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 282. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 283. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 284. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 285. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 286. NATO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 287. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 288. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 289. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 290. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 291. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 292. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 293. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 294. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 295. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 296. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 297. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 298. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 299. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 300. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 301. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 302. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 303. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 304. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 305. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
• TABLE 306. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
• TABLE 307. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
• TABLE 308. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
• TABLE 309. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
• TABLE 310. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 311. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 312. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 313. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 314. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 315. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 316. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
• TABLE 317. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
• TABLE 318. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET